|
|
|
|
|
by ig1
5108 days ago
|
|
The problem is that if these drugs end up entering the grey market in the developed world, it disincentives investment in the next generation of drugs. Huge amounts of money have to be raised to make a new drug. The cost of bringing a new drug to market is typically $800m-$1.2bn (i.e more than exit value of Instagram or Yammer is required just to get to launch). With treatments for viruses it gets even more problematic, in developing countries where regulations and medical practices are lax, a large number of people taking drugs in an uncontrolled manner can allow viruses to mutate making the drugs ineffective for everyone. The issue isn't as simple as good vs evil as the article makes out. There are complex ethical, economical and medical issues here and this article completely ignores that. |
|
Look at any commodity market, with no barriers to entry, no IP protection, thin margins, say: making bread. The logic that everybody will stop making bread because there's more money to be made in making iPads is false.
The general rule is: as long as there is money to be made, people will compete for this money.
There's a lot of money to be made in drugs and as long as it's true, companies will compete for this money, even if the margins won't be as great as they are today.
Look at http://en.wikipedia.org/wiki/List_of_pharmaceutical_companie...: the top pharma company makes $12bn profit on $62bn of revenue with $7bn spent on R&D.
The $12bn is a lot of wiggle room and twice the amount they spend on R&D. They are making profits hand over fist.
The $7bn total spent on R&D also puts your $1bn per drug into question - does the biggest pharma company can only do 7 new drugs per year (and I'm really generous in assuming all of that R&D goes into developing new drugs)?